Demographics and Treatment of Patients with Primary Membranoproliferative Glomerulonephritis in Japan Using a National Registry of Clinical Personal Records

Overview

Journal Clin Exp Nephrol

Publisher Springer

Specialty Nephrology

Date 2023 Jul 29

PMID 37515698

Authors

Naoki Nakagawa

Tomonori Kimura

Ryuichi Sakate

Yoshitaka Isaka

Ichiei Narita

Affiliations

Soon will be listed here.

Abstract

Background: Membranoproliferative glomerulonephritis (MPGN) is a rare glomerular injury that causes nephrotic syndrome and end-stage kidney disease. The nationwide demographics and treatment of Japanese patients with primary MPGN have not yet been reported.

Methods: We collected clinical personal records of patients with primary MPGN between 2015 and 2018 from the national registry organized by the Japanese Ministry of Health, Labour, and Welfare and investigated the characteristics of primary MPGN throughout Japan.

Results: Of 258 patients with primary MPGN, 199 and 59 showed nephrotic and non-nephrotic syndrome, respectively. The median age at onset was higher in patients with nephrotic syndrome than in those with non-nephrotic syndrome (45 [24-63] vs. 35 [14-53] years, respectively; P = 0.010). The use of oral prednisolone was significantly higher in patients with nephrotic syndrome than in those with non-nephrotic syndrome (73.9% vs. 59.3%, respectively; P = 0.032). When patients were divided into three age groups: adolescent and young adult group (≤ 39 years; n = 80), middle adult group (40-64 years; n = 111), and older adult group (≥ 65 years; n = 67), the use of oral prednisolone, cyclosporine, and mizoribine was significantly higher in the adolescent and young adult group than in the middle adult group. The mean dosage of oral prednisolone and mizoribine showed no differences among the three age groups.

Conclusion: The national registry of clinical personal records of primary MPGN could provide an informative insight into the characteristics, clinical features, and treatment approaches for patients with primary MPGN in Japan.

Citing Articles

Demographics and treatment of patients with primary nephrotic syndrome in Japan using a national registry of clinical personal records.

Nakagawa N, Kimura T, Sakate R, Wada T, Furuichi K, Okada H Sci Rep. 2023; 13(1):14771.

PMID: 37679492 PMC: 10485053. DOI: 10.1038/s41598-023-41909-5.

References

Wada T, Ishimoto T, Nakaya I, Kawaguchi T, Sofue T, Shimizu S . A digest of the Evidence-Based Clinical Practice Guideline for Nephrotic Syndrome 2020. Clin Exp Nephrol. 2021; 25(12):1277-1285. DOI: 10.1007/s10157-021-02098-5. View

Sethi S, Fervenza F . Membranoproliferative glomerulonephritis--a new look at an old entity. N Engl J Med. 2012; 366(12):1119-31. DOI: 10.1056/NEJMra1108178. View

Sofue T, Nakagawa N, Kanda E, Nagasu H, Matsushita K, Nangaku M . Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PLoS One. 2020; 15(7):e0236132. PMC: 7371174. DOI: 10.1371/journal.pone.0236132. View

Nishi S, Ubara Y, Utsunomiya Y, Okada K, Obata Y, Kai H . Evidence-based clinical practice guidelines for nephrotic syndrome 2014. Clin Exp Nephrol. 2016; 20(3):342-70. PMC: 4891386. DOI: 10.1007/s10157-015-1216-x. View

Yamamoto R, Imai E, Maruyama S, Yokoyama H, Sugiyama H, Nitta K . Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS). Clin Exp Nephrol. 2020; 24(6):526-540. PMC: 7248042. DOI: 10.1007/s10157-020-01864-1. View

Enzan N, Matsushima S, Ide T, Kaku H, Tohyama T, Funakoshi K . Clinical Characteristics and Contemporary Management of Patients With Cardiomyopathies in Japan　- Report From a National Registry of Clinical Personal Records. Circ Rep. 2021; 3(3):142-152. PMC: 7956877. DOI: 10.1253/circrep.CR-21-0001. View

Sakaguchi H, Hazikano H, Hasegawa O, Ito H . [Histological subtype of mesangiocapillary glomerulonephritis (MPGN type 1)]. Nihon Jinzo Gakkai Shi. 1984; 26(6):671-89. View

Nakagawa N, Mizuno M, Kato S, Maruyama S, Sato H, Nakaya I . Demographic, clinical characteristics and treatment outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulonephritis in Japan: A retrospective analysis of data from the Japan Renal Biopsy Registry. PLoS One. 2021; 16(9):e0257397. PMC: 8439563. DOI: 10.1371/journal.pone.0257397. View

Hayashida M, Kinjo T, Wada Y, Kitaguchi Y, Hanaoka M . Hierarchical cluster analysis based on disease-associated manifestations of patients with lymphangioleiomyomatosis: An analysis of the national database of designated intractable diseases of Japan. Respir Investig. 2022; 60(4):570-577. DOI: 10.1016/j.resinv.2022.03.003. View

10.

Kimura T, Ikeuchi H, Yoshino M, Sakate R, Maruyama S, Narita I . Profiling of kidney involvement in systemic lupus erythematosus by deep learning using the National Database of Designated Incurable Diseases of Japan. Clin Exp Nephrol. 2023; 27(6):519-527. PMC: 10191896. DOI: 10.1007/s10157-023-02337-x. View

11.

Sugiyama H, Yokoyama H, Sato H, Saito T, Kohda Y, Nishi S . Japan Renal Biopsy Registry: the first nationwide, web-based, and prospective registry system of renal biopsies in Japan. Clin Exp Nephrol. 2011; 15(4):493-503. DOI: 10.1007/s10157-011-0430-4. View

12.

Nakagawa N, Sofue T, Kanda E, Nagasu H, Matsushita K, Nangaku M . J-CKD-DB: a nationwide multicentre electronic health record-based chronic kidney disease database in Japan. Sci Rep. 2020; 10(1):7351. PMC: 7192920. DOI: 10.1038/s41598-020-64123-z. View

13.

Nakagawa N, Hasebe N, Hattori M, Nagata M, Yokoyama H, Sato H . Clinical features and pathogenesis of membranoproliferative glomerulonephritis: a nationwide analysis of the Japan renal biopsy registry from 2007 to 2015. Clin Exp Nephrol. 2017; 22(4):797-807. DOI: 10.1007/s10157-017-1513-7. View

14.

Kawamura T, Usui J, Kaseda K, Takada K, Ebihara I, Ishizu T . Primary membranoproliferative glomerulonephritis on the decline: decreased rate from the 1970s to the 2000s in Japan. Clin Exp Nephrol. 2012; 17(2):248-54. DOI: 10.1007/s10157-012-0690-7. View

15.

Iitaka K, ISHIDATE T, Hojo M, Kuwao S, Kasai N, Sakai T . Idiopathic membranoproliferative glomerulonephritis in Japanese children. Pediatr Nephrol. 1995; 9(3):272-7. DOI: 10.1007/BF02254182. View

16.

Okuda Y, Ishikura K, Hamada R, Harada R, Sakai T, Hamasaki Y . Membranoproliferative glomerulonephritis and C3 glomerulonephritis: frequency, clinical features, and outcome in children. Nephrology (Carlton). 2014; 20(4):286-92. DOI: 10.1111/nep.12382. View

17.

Kawasaki Y, Kanno S, Ono A, Suzuki Y, Ohara S, Sato M . Differences in clinical findings, pathology, and outcomes between C3 glomerulonephritis and membranoproliferative glomerulonephritis. Pediatr Nephrol. 2016; 31(7):1091-9. DOI: 10.1007/s00467-015-3307-z. View

18.

McGrogan A, Franssen C, de Vries C . The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2010; 26(2):414-30. DOI: 10.1093/ndt/gfq665. View

19.

Braden G, Mulhern J, OShea M, Nash S, Ucci Jr A, Germain M . Changing incidence of glomerular diseases in adults. Am J Kidney Dis. 2000; 35(5):878-83. DOI: 10.1016/s0272-6386(00)70258-7. View

20.

Nagasu H, Yano Y, Kanegae H, Heerspink H, Nangaku M, Hirakawa Y . Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database. Diabetes Care. 2021; 44(11):2542-2551. PMC: 8546274. DOI: 10.2337/dc21-1081. View